PremiumThe FlyAscendis Pharma price target raised to $215 from $180 at Oppenheimer Ascendis Pharma price target raised to $210 from $205 at RBC Capital Ascendis Pharma price target raised to $212 from $181 at Wedbush PremiumRatingsAscendis Pharma: Strong Market Position and Growth Potential Justify Buy Rating Ascendis Pharma Reports Strong Q1 2025 Financial Results and Strategic Progress Ascendis Pharma Reports Q1 2025 Financial Results with Improved Losses PremiumThe FlyReddit initiated, Target downgraded: Wall Street’s top analyst calls Ascendis Pharma initiated with an Outperform at RBC Capital Strong Initial Demand and Encouraging Payor Coverage Drive Buy Rating for Ascendis Pharma’s Yorvipath 
